Glaxosmithkline Intellectual Property Development Limited

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Medshine Discovery Inc.

Other

Cspc Zhongqi Pharmaceutical Technology (shijiazhuang) Co., Ltd.

Hua Medicine (shanghai) Ltd.

Cstone Pharmaceuticals

Cstone Pharmaceuticals (shanghai) Co., Ltd.

Fujian Akeylink Biotechnology Co., Ltd.

Cgenetech (suzhou, China) Co., Ltd.

Hubei Bio-pharmaceutical Industrial Technological Institute Inc.

Cisen Pharmaceutical Co., Ltd.

D3 Bio (wuxi) Co., Ltd.

Qingdao Huanghai Pharmaceutical Co., Ltd.

Fujian Cosunter Pharmaceutical Co., Ltd.

Chengde Wu

Shuhui Chen

Tao Yu

Chunli Shen

Huiping Amy Guan

Mui Cheung

Ning Li

Zhen Gong

Qinghua Mao

Zhiliu Zhang

Jian Li

Hilary Schenck Eidam

Yi Li

Donghui Qin

Jiahu Wu

Haiyu Yu

Xiquan Zhang

Guoping Hu

Xin Tian

Bo Gao

Ting Wang

Li Chen

Yong Liang Liu

Yong Liu

Yong Wang

Yi Bu Li

Charles Z Ding

Zheng Wang

Feng Guo

Yong Xu

Jeffrey Michael Axten

Yi Zhang

Jie Gandalf Yan

Jin She

Michael P DeMartino

Jikui Sun

Lu Huang

Changjun Wang

Xiaobing Yan

Xuehai Wang

Xiawei Wei

Haiying Yang

Shenglin Chen

Michael P Demartino

Lu Gan

Nengyang Shi

Yong Huang

Ronghua Tu

Hailiang Chen

Wenjie Sun

Wei Zheng

Zongbin Li

Jie Shen

Ning Liu

Zhongwen Yang

Yang Yue

Qiang Xiao

Ning Jiang

XiaWei Wei

Jing Yang

Wen Zhou

Yan Hu

Lingwei Kong

Li'e Li

Yaxian Cai

Hua Tian

Yanping Yu

Jing Tang

Wenjie Xu

Dongling Hao

Kaushik Raha

Aaron Bayne Miller

Xiaojuan Lin

Guanglong Sun

Shengbin Zhang

Diliang Guo

Yusheng Fu

Huanyu Bian

Xuwen Zhang

Zhenyu He

Jing Yu

Quan Liu

Peipei Jiang

Zhemin Rong

Yuejiao Duan

Huiping Guan

Amy Huiping Guan

Compounds as SGLT2/DPP4 dual inhibitors, and application in preparation of medicines as the SGLT2/DPP4 dual inhibitors. A compound represented by formula (I), and an isomer or pharmaceutically acceptable salt thereof are specifically involved.

SGLT2/DPP4 inhibitor and application thereof

A Spiro compound serving as an ERK inhibitor, and an application thereof in preparing a drug for treating an ERK-related disease. The present invention specifically relates to a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.

Spiro compound serving as ERK inhibitor, and application thereof

A class of compounds as a SGLT1/SGLT2/DPP4 triple inhibitor, and an application in preparation of a drug serving as the SGLT1/SGLT2/DPP4 triple inhibitor. Compounds represented by formula (I), and isomers and pharmaceutically-acceptable salts thereof are specifically involved.

SGLTS/DPP4 inhibitor and application thereof

Disclosed are a solid form and a crystal form of a compound represented by formula (I) used as a BRD4 inhibitor, a preparation method therefor, and an application thereof in the preparation of a medicine for treating BRD4-related diseases. (I).

BRD4 inhibitor compound in solid form and preparation method therefor and use thereof

A glucoside derivative that acts as an SGLT1 inhibitor and an application thereof in the preparation of a drug for SGLT1 related diseases. Specifically disclosed is a compound represented by formula (II), a tautomer thereof or a pharmaceutically acceptable composition thereof.

Glucoside derivative that acts as SGLT1 inhibitor and application thereof

Disclosed are a class of macrocyclic derivatives, a preparation method therefor, a pharmaceutical composition containing the derivatives, and the use thereof as therapeutic agents, particularly as XIa factor inhibitors and in the preparation of a drug for treating and preventing thromboembolisms and other diseases. Particularly disclosed are compounds shown by formula (I), an isomer thereof and a pharmaceutically acceptable salt thereof.

Macrocyclic derivatives acting as XIa factor inhibitor

The present application belongs to the field of medicine. In particular, the present application relates to a diarylthiohydantoin compound as an androgen receptor antagonist or a pharmaceutically acceptable salt thereof, a preparation method of the same, a pharmaceutical composition comprising the compound, and a use thereof in treating a cell proliferative disease mediated by androgen. The compound of the present application has good antagonistic effect on androgen receptor and exhibits excellent antitumor effect.

Diarylthiohydantoin compound as androgen receptor antagonist

Provided are crystal forms A, B, C and D of a compound of formula (I), and application of the crystal forms in the preparation of drugs for treating ASK1-related diseases.

Crystal form as ASK1 inhibitor and preparation method and application thereof

The present application relates to the field of medicine. Specifically, disclosed are a compound of formula (I), a preparation method therefor, and a pharmaceutical composition comprising the compound.

Heterocyclic compound

This invention relates to novel compounds according to Formula (I) which are inhibitors of furin, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of fibrotic diseases, including pulmonary fibrosis, renal fibrosis, liver fibrosis, skin fibrosis, ocular fibrosis, cardiac fibrosis, and other miscellaneous fibrotic conditions. The disclosed compounds may also be useful for treating other furin-mediated conditions, including but not limited to, hypertension, cancer, infectious diseases, and genetic disorders (e.g., cystic fibrosis (CF)), and neurodegenerative disorders.

Furin inhibitors

Disclosed are a class of BTK kinase inhibitor compounds with a high activity and a high selectivity and the use thereof in the preparation of a drug for treating BTK target-related diseases. Specifically, disclosed are a compound shown as formula (I), and an isomer and a pharmaceutically acceptable salt thereof.

Substituted pyrazlo[3,4-c]pyridines as selective BTK kinase inhibitors

A novel five-membered heteroaromatic imidazole compound and use thereof is disclosed herein. Specifically, disclosed is a compound as shown in formula (III) or a pharmaceutically acceptable salt thereof. Also disclosed is a method for treating a disease related to GLP-1 receptor such as type II diabetes. 

Five-membered heteroaryl-fused imidazole compound and application thereof

The present invention relates to a class of thienodiazepine derivatives and an application thereof in the preparation of a drug for the treatment of diseases associated with bromodomain and extra-terminal (BET) Bromodomain inhibitors. Specifically, the present invention relates to compounds represented by formulas (I) and (II), as well as pharmaceutically acceptable salts thereof. 

Thienodiazepine derivatives and application thereof

Disclosed in the present invention are a compound as shown in formula (II), a tautomer or a pharmaceutically acceptable salt thereof, and also disclosed is the use thereof in preparing a drug for treating an ASK1-associated disease. 

Pyridine derivative as ASK1 inhibitor and preparation method and use thereof

Growing community of inventors

Shanghai, China

Chengde Wu